Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07999415 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| PF-07999415 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-07999415 | BIOLOGICAL | Participants will receive single doses of PF-07999415. |
| Placebo | DRUG | Participants will receive matching placebo. |
Inclusion Criteria: * Male and female participants of non-childbearing potential aged 18 to 65 years, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Body Mass Index (BMI...
PF-07999415 is an investigational monoclonal antibody being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development for use in healthy adults. The drug is being studied to understand how different amounts are tolerated and how they act in the body.
PF-07999415 is being studied in healthy adults as part of a Phase 1 clinical trial. The trial aims to evaluate how different doses of the study medicine are tolerated and how they behave in the body. It is not yet approved for any medical condition.
PF-07999415 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and pharmacokinetics in healthy adults.
PF-07999415 is in Phase 1 clinical development. The ongoing trial is a randomized, double-blind, placebo-controlled study in healthy adults. The trial is active but not recruiting participants, and it is being conducted in Belgium.
PF-07999415 is being studied in a Phase 1 clinical trial with the identifier NCT06965465. The trial is titled 'A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults.' It enrolls 32 healthy adult participants and is active but not recruiting.
PF-07999415 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The ongoing trial is evaluating the drug's tolerability and pharmacokinetics in healthy adults, and it has not yet progressed to later-stage trials or regulatory approval.